ASSAY FOR CARDIAC TROPONIN AUTOANTIBODIES

• US 20080305512A1
• Filed: 11/02/2007
• Published: 12/11/2008
• Est. Priority Date: 10/26/2006
• Status: Abandoned Application

• Current Assignee: Abbott Laboratories Incorporated
• Original Assignee: Abbott Laboratories Incorporated
• Inventors: Doss, Robert C., Adamczyk, Maciej, Mattingly, Phillip G., Brashear, Roy Jeffrey
• Application Number:
  US11/934,688
• Publication Number:
  US 20080305512A1
• Time in Patent Office: Days
• US Class Current: 435/28
• CPC Class Codes: G01N 2800/324 Coronary artery diseases, e.g. angina pectoris, myocardial infarction
• CPC Class Codes: G01N 2800/325 Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
• CPC Class Codes: G01N 33/54326 Magnetic particles
• CPC Class Codes: G01N 33/564 for pre-existing immune complex or autoimmune disease , i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
• CPC Class Codes: G01N 33/6854 Immunoglobulins
• CPC Class Codes: G01N 33/6887 from muscle, cartilage or connective tissue

Abstract

The invention provides among other things methods and kits based on assaying for cardiac troponin autoantibodies, either in conjunction with an assay for cardiac troponin and/or as an independent indicator of cardiac pathology, such as myocarditis, cardiomyopathy, and/or ischemic heart disease. Assay methods of the invention can be employed among other things to identify cardiac pathology, or risk thereof, in subjects who have an autoimmune disease or who are related to an individual with an autoimmune disease. In particular embodiments, the invention also provides a method of determining whether a subject having, or at risk for, a cardiac pathology is a candidate for immunosuppressive therapy or immunoabsorption therapy. The invention also provides kits and kit components that are useful for performing the methods of the invention.

Claims

1-61. -61. (canceled)

62. A diagnosis method of dilated cardiomyopathy, which comprises measuring an amount of anti-cardiac troponin I autoantibody.

63. A method to aid in the assessment of an individual'"'"'s risk of developing a myocardial disorder, the method comprising:

(a) measuring one or more in vitro antibodies to a cardiac troponin and

(b) correlating a value or values obtained in step (a) to the individual'"'"'s risk of developing a myocardial disorder.

64. The method according to claim 63 wherein the cardiac troponin comprises troponin T and troponin I.

65. The method according to claim 63 wherein the cardiac troponin is troponin I or troponin T.

66. The method according to claim 63 wherein the antibodies are of the immunoglobin M class.

67. The method according to claim 63 wherein the antibodies are of the immunoglobin G class.

68. The method according to claim 63 wherein step (a) further comprises measuring a marker selected from the group consisting of a cardiac troponin, a natriuretic peptide or a natriuretic peptide-related marker, an inflammation marker, D-dimer, cholesterol, homocysteine, adiponectin, soluble CD40 ligand, myeloperoxidase, placenta growth factor, and ischemia modified albumin.

69. The method according to claim 68 wherein the marker is a cardiac troponin.

70. The method according to claim 68 wherein the marker is brain derived natriuretic peptide (BNP) or a BNP-related marker.

71. A kit comprising a cardiac troponin and auxiliary reagents appropriate for measurement of an antibody to the cardiac troponin.